<DOC>
	<DOCNO>NCT00003647</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Injecting allovectin-7 person 's melanoma cell may make body build immune response kill tumor cell . PURPOSE : Randomized phase III trial compare effectiveness dacarbazine without immunotherapy treat patient stage III stage IV melanoma .</brief_summary>
	<brief_title>Chemotherapy With Without Immunotherapy Treating Patients With Stage III Stage IV Melanoma</brief_title>
	<detailed_description>OBJECTIVES : I . Demonstrate either improvement median time disease progression least 2 month decrease rate objective clinical response OR improvement least 15 % rate objective clinical response decrease median time disease progression patient stage III IV melanoma receive dacarbazine Allovectin-7 compare patient receive dacarbazine alone . II . Determine benefit , risk , side effect regimens patient population . PROTOCOL OUTLINE : This randomize , multicenter study . Patients stratify accord sex , age , spread disease ( cutaneous nodal vs visceral disease ) . Patients randomize one two treatment arm . Arm I : Patients receive dacarbazine IV 1 hour day 0 . Arm II : Patients receive treatment arm I . Patients also receive Allovectin-7 intratumorally day 3 10 . Patients stable respond disease may receive additional course every 28 day . Patients follow every 4 month . PROJECTED ACCRUAL : A total 280 patient ( 140 arm ) accrue study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Histologically confirm stage III IV melanoma 1 metastatic tumor surgery deem curative option Dacarbazine indicate first line chemotherapy At least 1 measurable tumor least 1 cm2 great 100 cm2 No history brain metastasis Prior/Concurrent Therapy Biologic therapy : At least 4 week since prior biologic therapy Chemotherapy : See Disease Characteristics ; No prior chemotherapy Endocrine therapy : No concurrent immunosuppressive drug Radiotherapy : At least 4 week since prior radiotherapy Surgery : At least 2 week since prior major surgery Other : No concurrent anticancer drug therapy experimental therapy Patient Characteristics Age : 18 Performance status : Karnofsky 80100 % Life expectancy : At least 24 week Hematopoietic : WBC least 3,000/mm3 ; Platelet count least 100,000/mm3 ; Hemoglobin least 9 g/dL Hepatic : Bilirubin great 2.0 mg/dL ; SGOT/SGPT le 3 time upper limit normal ( ULN ) ; PT/PTT normal ; Albumin normal ; LDH great 2 time ULN Renal : Creatinine great 2.0 mg/dL Cardiovascular : No uncontrolled hypertension ; No New York Heart Association class III IV disease Other : HIV negative ; Not pregnant nursing ; Negative pregnancy test ; Fertile patient must use effective contraception ; No active autoimmune disease ; No active infection require parenteral antibiotic ; No uncontrolled diabetes mellitus ; No prior malignancy within past 5 year except skin cancer stage 0II cervical cancer ; No significant psychiatric disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>adult solid tumor</keyword>
	<keyword>body system/site cancer</keyword>
	<keyword>cancer</keyword>
	<keyword>melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
	<keyword>skin tumor</keyword>
	<keyword>solid tumor</keyword>
	<keyword>stage III melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>stage , melanoma</keyword>
</DOC>